We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OKLO Builds on Groves Progress to Expand Isotope Business
Read MoreHide Full Article
Key Takeaways
OKLO's Groves-1 reactor got DOE startup authorization in July 2026 and achieved first criticality in August.
OKLO completed substantial construction in 229 days, gaining experience to streamline future isotope projects.
OKLO secured ytterbium-176 for cancer-treatment isotopes, while its Idaho lab may generate earlier revenues.
Oklo Inc. (OKLO - Free Report) is advancing its plans to establish a domestic isotope supply chain through its Groves-1 Isotope Test Reactor in Texas. The facility is designed to support the development of isotopes used in cancer treatments, manufacturing, scientific research and national security. The project has already cleared important regulatory and operational milestones, including startup authorization from the U.S. Department of Energy (“DOE”) on July 23, 2026, and first criticality on Aug. 5, 2026.
OKLO developed Groves on privately owned land using private funding and commercially sourced equipment, alongside components manufactured by the company. The facility reached first criticality in just over 11 months from groundbreaking, with substantial construction completed in 229 days. The project provided experience in reactor construction, equipment installation, regulatory reviews and nuclear operations. Management plans to apply these lessons to future isotope facilities, potentially improving project execution and shortening development timelines.
OKLO is also strengthening its isotope supply chain. In September 2026, the company received two grams of enriched ytterbium-176, which can be converted into lutetium-177 through reactor irradiation. Lutetium-177 is used in targeted cancer treatments. Securing this material supports the company's efforts to develop domestic production capabilities and reduce reliance on overseas suppliers.
From an investment perspective, Groves gives OKLO practical operating experience to support its isotope business expansion. Management expects research-scale isotope production after further commissioning, while its NRC-licensed Idaho laboratory may generate earlier commercial revenues. Although commercial-scale production remains under development, these initiatives provide opportunities to expand OKLO's business beyond nuclear power generation.
The growing demand for reliable, carbon-free electricity is encouraging greater investment in advanced nuclear technologies. Alongside isotope production, the development of smaller nuclear reactors is creating opportunities to serve utilities, industrial customers and data centers.
NuScale Power (SMR - Free Report) is among the leading developers of small modular reactor technology and is the first company to receive U.S. Nuclear Regulatory Commission approval for a design. NuScale Power is working with partners on projects in the United States and overseas, including Romania, while advancing plans to support large-scale power deployment. NuScale Power believes its modular reactors can deliver reliable, carbon-free electricity for utilities, industries and AI-driven data centers, keeping NuScale Power at the forefront of the commercial small modular reactor market.
NANO Nuclear Energy (NNE - Free Report) is focused on smaller microreactors through its KRONOS MMR design. The company is preparing to begin the NRC licensing process for its first deployment at the University of Illinois after its construction permit application is formally accepted. At the same time, NANO Nuclear is pursuing opportunities in AI data centers, industrial facilities and defense applications while expanding partnerships that could support future commercialization.
The Zacks Rundown on OKLO
Shares of Oklo have lost more than 80% over the past year.
Image Source: Zacks Investment Research
OKLO currently has an average brokerage recommendation (ABR) of 1.92 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 24 brokerage firms.
Image Source: Zacks Investment Research
See how the Zacks Consensus Estimate for OKLO’s earnings has been revised over the past 90 days.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
OKLO Builds on Groves Progress to Expand Isotope Business
Key Takeaways
Oklo Inc. (OKLO - Free Report) is advancing its plans to establish a domestic isotope supply chain through its Groves-1 Isotope Test Reactor in Texas. The facility is designed to support the development of isotopes used in cancer treatments, manufacturing, scientific research and national security. The project has already cleared important regulatory and operational milestones, including startup authorization from the U.S. Department of Energy (“DOE”) on July 23, 2026, and first criticality on Aug. 5, 2026.
OKLO developed Groves on privately owned land using private funding and commercially sourced equipment, alongside components manufactured by the company. The facility reached first criticality in just over 11 months from groundbreaking, with substantial construction completed in 229 days. The project provided experience in reactor construction, equipment installation, regulatory reviews and nuclear operations. Management plans to apply these lessons to future isotope facilities, potentially improving project execution and shortening development timelines.
OKLO is also strengthening its isotope supply chain. In September 2026, the company received two grams of enriched ytterbium-176, which can be converted into lutetium-177 through reactor irradiation. Lutetium-177 is used in targeted cancer treatments. Securing this material supports the company's efforts to develop domestic production capabilities and reduce reliance on overseas suppliers.
From an investment perspective, Groves gives OKLO practical operating experience to support its isotope business expansion. Management expects research-scale isotope production after further commissioning, while its NRC-licensed Idaho laboratory may generate earlier commercial revenues. Although commercial-scale production remains under development, these initiatives provide opportunities to expand OKLO's business beyond nuclear power generation.
The growing demand for reliable, carbon-free electricity is encouraging greater investment in advanced nuclear technologies. Alongside isotope production, the development of smaller nuclear reactors is creating opportunities to serve utilities, industrial customers and data centers.
Advanced Nuclear Reactor Developers Eye Growth Opportunities
NuScale Power (SMR - Free Report) is among the leading developers of small modular reactor technology and is the first company to receive U.S. Nuclear Regulatory Commission approval for a design. NuScale Power is working with partners on projects in the United States and overseas, including Romania, while advancing plans to support large-scale power deployment. NuScale Power believes its modular reactors can deliver reliable, carbon-free electricity for utilities, industries and AI-driven data centers, keeping NuScale Power at the forefront of the commercial small modular reactor market.
NANO Nuclear Energy (NNE - Free Report) is focused on smaller microreactors through its KRONOS MMR design. The company is preparing to begin the NRC licensing process for its first deployment at the University of Illinois after its construction permit application is formally accepted. At the same time, NANO Nuclear is pursuing opportunities in AI data centers, industrial facilities and defense applications while expanding partnerships that could support future commercialization.
The Zacks Rundown on OKLO
Shares of Oklo have lost more than 80% over the past year.
OKLO currently has an average brokerage recommendation (ABR) of 1.92 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 24 brokerage firms.
See how the Zacks Consensus Estimate for OKLO’s earnings has been revised over the past 90 days.
The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.